FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma

ABSTRACT:

SUBMITTER: Corren J 

PROVIDER: S-EPMC12926823 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature